Galapagos NV (AMS: GLPG)
Market Cap | 1.73B |
Revenue (ttm) | 261.40M |
Net Income (ttm) | 282.59M |
Shares Out | 65.90M |
EPS (ttm) | 4.29 |
PE Ratio | 55.02 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 57,249 |
Open | 25.90 |
Previous Close | 26.30 |
Day's Range | 25.52 - 25.98 |
52-Week Range | 22.00 - 39.00 |
Beta | 0.09 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Oct 30, 2024 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2023, VLK's revenue was 667.35 million, an increase of 12.56% compared to the previous year's 592.87 million. Earnings were 118.45 million, an increase of 53.02%.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/j/w/press11-2623038.jpg)
Galapagos receives transparency notification from FMR LLC
Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Galapagos up 10% as major shareholder intends to talk about strategy
![](https://cdn.benzinga.com/files/images/story/2024/08/26/pharma-lab-worker-ai.png?optimize=medium&dpr=1&auto=jpg&height=480&width=720&fit=crop)
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos NV (NASDAQ: GLPG) stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing . EcoR1 Capital is now planning to talk to the Belgia...
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
![](https://cdn.benzinga.com/files/images/story/2024/08/26/movers-image_1.jpeg?optimize=medium&dpr=1&auto=jpg&height=480&width=720&fit=crop)
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday. Shares of Galapagos NV (NASDAQ: GLPG) rose sharply during Monday's session after Ecor1 Capital reported a...
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157592785/image_2157592785.jpg?io=getty-c-w1536)
Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with rrNHL. Read more on GLPG stock here.
Galapagos gains after FDA nod for lymphoma trial
![](https://cdn.snapi.dev/images/v1/4/l/press4-2605279.jpg)
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has ...
![](https://cdn.snapi.dev/images/v1/o/t/press15-2562285.jpg)
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
BridGene Eligible to Receive Up to $15 9 Million in Total Payments SAN JOSE, Calif. , Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for tra...
![](https://cdn.snapi.dev/images/v1/e/3/press1-2562266.jpg)
Galapagos reports half-year 2024 financial results and provides second quarter business update
Webcast presentation with management on 2 August 2024, at 14:00 CET / 8:00 AM ET, www.glpg.com
![](https://cdn.snapi.dev/images/v1/4/v/press6-2480548.jpg)
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T ...
![](https://cdn.snapi.dev/images/v1/4/b/press7-2454843.jpg)
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc...
![](https://cdn.snapi.dev/images/v1/t/m/press10-2454847.jpg)
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma...
![](https://cdn.snapi.dev/images/v1/w/n/press12-2435963.jpg)
Galapagos creates new subscription right plans
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new su...
![](https://cdn.snapi.dev/images/v1/d/x/press6-2433243.jpg)
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decen...
![](https://cdn.snapi.dev/images/v1/y/q/press18-2407484.jpg)
Galapagos reports first quarter 2024 financial results
Webcast presentation with management on 3 May 2024, at 14:00 CET / 8:00 am ET, www.glpg.com
![](https://cdn.snapi.dev/images/v1/k/x/press18-2401046.jpg)
Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company's Annual and Extraordinary Shareholders' Meetings (AGM ...
![](https://cdn.snapi.dev/images/v1/j/w/press6-2357426.jpg)
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
![](https://cdn.snapi.dev/images/v1/p/w/press13-2347129.jpg)
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings
Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and E...
![](https://cdn.snapi.dev/images/v1/p/k/press10-2342702.jpg)
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Exec...
![](https://cdn.snapi.dev/images/v1/g/p/press6-2289623.jpg)
Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operati...
![](https://cdn.snapi.dev/images/v1/k/z/press17-2279218.jpg)
Galapagos presents at EBMT-EHA annual meeting 2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
![](https://cdn.snapi.dev/images/v1/e/h/press11-2254063.jpg)
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Al...
![](https://cdn.snapi.dev/images/v1/4/l/press17-2217240.jpg)
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (N...
![](https://cdn.snapi.dev/images/v1/p/a/press7-2215447.jpg)
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of...